What Are Large Granular Lymphocytes and What Do They Do?

Large granular lymphocytes, usually called LGLs, are a subset of white blood cells whose job is to patrol the bloodstream looking for virus-infected cells and tumor cells, then kill them. They get their name from their appearance under a microscope: they are larger than most lymphocytes and contain distinctive granules packed with cell-killing proteins.¹ LGLs make up a small but critical arm of your immune defense, and the biology behind how they work, how they develop, and what happens when they malfunction is more layered than the name suggests.

What LGLs Look Like and Why That Matters

Under a standard light microscope, an LGL stands out. Most lymphocytes are small, round cells with a thin rim of cytoplasm and not much else to see. LGLs are noticeably bigger, with a generous amount of pale cytoplasm filled with azurophilic granules, tiny organelles that stain a reddish-purple color.¹ Those granules are not just decorative. They contain perforin and granzyme B, the two main weapons LGLs use to destroy target cells. Perforin punches holes in the membrane of the target cell, and granzyme B slips through those holes to trigger the cell’s self-destruct program.²

In most healthy adults, LGLs account for roughly 10 to 15 percent of the lymphocytes circulating in peripheral blood. That translates to somewhere around 200 to 400 cells per microliter. Finding them on a blood smear is routine and normal. The question only becomes medically interesting when their numbers climb well above that range and stay there.

The Two Main Types

LGLs are not a single cell type. The term covers two functionally related but biologically distinct populations: cytotoxic T cells (specifically the CD8-positive subset) and natural killer cells. Under the microscope they look nearly identical, which is exactly why the umbrella term “large granular lymphocyte” stuck. Telling them apart requires immunophenotyping, a lab technique that identifies specific proteins on the cell surface.

T-cell LGLs carry the CD3 marker, which tags them as part of the adaptive immune system. They have rearranged their T-cell receptor genes, meaning each clone recognizes a specific target. NK-cell LGLs lack CD3 but typically express CD56 and CD16.³ They belong to the innate immune system and do not need to have encountered a particular pathogen before to attack it. NK cells were actually discovered when researchers studying T cells kept finding unexplained killing activity in mice that had never been immunized, a background signal that turned out to be an entirely separate cell type.⁴

Both types share the same basic killing toolkit. They can deploy perforin and granzyme B from their granules, or they can use an alternative route: the Fas ligand pathway. In this second mechanism, the LGL presents a molecule called Fas ligand on its surface, which binds to the Fas receptor on the target cell and triggers apoptosis directly, without the need to release any granule contents.² The existence of two killing pathways gives LGLs flexibility: if one route is blocked or ineffective against a particular target, the other can still work.

How LGLs Develop and What Keeps Them in Check

A signaling molecule called interleukin-15 (IL-15) is central to the life cycle of LGLs. IL-15 drives their differentiation, helps them multiply, activates their killing functions, and keeps them alive.⁵ In a healthy person, this system is tightly regulated: IL-15 rises when LGLs are needed, such as during a viral infection, and falls back when the threat clears. The balance between growth signals and death signals determines how many LGLs you have at any given moment.

Chronic stimulation can disrupt this balance. Persistent viral infections, including cytomegalovirus (CMV), Epstein-Barr virus, and HIV, can act as ongoing triggers that push LGLs to keep proliferating long after a normal immune response would have wound down. Autoimmune conditions, where the body’s own tissues provide the constant antigenic signal, can do the same thing. This chronic stimulation is thought to be the initial spark behind both reactive LGL expansions and, in some cases, outright LGL leukemia.

When LGL Numbers Rise Without Cancer

Not every increase in LGL counts means something sinister. Reactive LGL expansions are relatively common and can be driven by viral infections, organ transplants, or autoimmune disease. The cells expand because the immune system is responding to a real or perceived threat. In many of these situations, the expansion is polyclonal, meaning the extra LGLs come from many different clones, not a single runaway population. Polyclonal expansions usually resolve once the underlying trigger is addressed.

One diagnostic wrinkle is that clonal CD8-positive T-cell populations show up in healthy people, too, especially with age. As the T-cell repertoire narrows over time, individual clones can become disproportionately large without causing any disease. A study evaluating clonality testing for T-LGL leukemia found that the presence of clonal CD8+CD57+ cells in blood is common in healthy individuals and patients with reactive conditions, and does not necessarily indicate malignancy.⁶ This overlap between normal aging and early disease makes LGL disorders tricky to diagnose purely from a lab number.

LGL Leukemia

When a single clone of LGLs expands and persists for months, the condition crosses into the territory of large granular lymphocytic leukemia (LGLL). Despite the alarming name, most forms of LGLL are indolent, meaning they progress slowly and many patients live for years without needing treatment.⁷ The exception is aggressive NK-cell leukemia, which is a rare and fast-moving disease with a much worse prognosis.

LGLL falls into three recognized subtypes. T-cell LGL leukemia is by far the most common. Chronic lymphoproliferative disorder of NK cells (CLPD-NK) is the indolent NK counterpart. Aggressive NK-cell leukemia is the rarest and most dangerous variant.⁸ Interestingly, even under the microscope the leukemic LGLs are usually indistinguishable from normal LGLs. One exception involves a subset of patients carrying STAT3 mutations, whose leukemic cells tend to be smaller than typical LGLs, with a median diameter under 13 micrometers.⁸

The median age at diagnosis is around 66 to 67 years, with roughly 60 percent of patients diagnosed after age 65.⁹ It affects men and women at similar rates.¹⁰ Though women in one population study were diagnosed at a slightly younger age than men.

Symptoms and What LGL Leukemia Actually Does to the Body

The hallmark problems caused by LGLL are not the ones most people associate with leukemia. Patients rarely present with massive white cell counts or obvious tumor masses. Instead, the most common clinical features are neutropenia, anemia, and low platelet counts.⁷ Neutropenia, a shortage of neutrophils, is the biggest practical concern. Neutrophils are the first-responder white blood cells that fight bacterial infections, so patients with severe neutropenia tend to get recurrent, sometimes serious, infections. In indolent LGLL, these infectious complications are the main cause of death.⁷

How exactly the leukemic LGLs cause neutropenia is still not fully understood. Multiple mechanisms seem to cooperate: the clonal LGLs may directly kill neutrophil precursors in the bone marrow through their normal cytotoxic machinery, they may crowd out normal blood-cell production, and abnormal antibodies circulating in the blood may target neutrophils as well.¹¹ The multifactorial nature of the neutropenia helps explain why treatment responses can be unpredictable.

The Autoimmune Connection

One of the most striking features of LGLL is how frequently it co-occurs with autoimmune diseases, especially rheumatoid arthritis (RA). The overlap is so strong that researchers have debated for years whether LGLL and RA are two separate diseases that happen to co-occur or two faces of the same underlying immune dysfunction.¹² Other autoimmune conditions linked to LGLL include Sjögren’s syndrome, autoimmune thyroid disease, vasculitis, and autoimmune cytopenias.¹³

The relationship with RA goes particularly deep. Felty’s syndrome, a rare complication of RA characterized by neutropenia and an enlarged spleen, looks clinically almost identical to T-LGL leukemia with rheumatoid arthritis. Both conditions share the same genetic marker, HLA-DR4.¹⁴ And in a study of 14 Felty’s syndrome patients, STAT3 mutations were found in 43 percent of cases, a rate comparable to what is seen in T-LGL leukemia itself.¹⁵ The growing consensus is that Felty’s syndrome and LGL leukemia sit on the same disease spectrum rather than being distinct entities.

The Role of STAT3 Mutations

The discovery that STAT3 mutations are common in T-LGL leukemia reshaped how researchers think about the disease. In a landmark study, these mutations were found in about 40 percent of patients with LGLL.¹⁶ STAT3 is a signaling protein that, when activated, promotes cell survival and proliferation. In LGLL, the mutations sit in a region of the gene that keeps the protein stuck in an “on” position, driving the leukemic cells to survive when they should be dying off.

The mutations also have clinical consequences beyond just causing disease. Patients carrying STAT3 mutations are more likely to present with neutropenia and rheumatoid arthritis than those without.¹⁶ A further study found that the CD8-positive T-LGL leukemia patients who were CD16-positive and CD56-negative represented a subset particularly enriched for STAT3 mutations and associated with neutropenia. Meanwhile, a separate subtype of LGLL involving CD4-positive cells harbors mutations in a related gene, STAT5b, rather than STAT3.¹⁷ These findings are relevant to treatment decisions, as we will see below, and they point toward future targeted therapies.

How LGL Leukemia Is Diagnosed

Diagnosing LGLL can be surprisingly difficult because the cells look normal, the disease progresses slowly, and many patients are found incidentally when blood work reveals an unexplained low neutrophil count or a persistent lymphocytosis. There is no single test that clinches the diagnosis. Instead, clinicians piece together a picture from blood counts, morphology, immunophenotyping, and clonality testing.

Flow cytometry is the first major diagnostic step. It identifies the surface markers on the expanded lymphocyte population, determining whether the cells are T-cell or NK-cell derived and flagging aberrant antigen expression. In one study of T-LGL leukemia and NK-LGL leukemia patients, abnormal antigen expression was present in all cases, providing reliable evidence that the population was neoplastic rather than reactive.¹⁸

Clonality testing adds another layer. For T-cell cases, analyzing Vβ usage by flow cytometry is a fast and sensitive way to identify whether the T cells share a single T-cell receptor rearrangement, which would point to a clonal expansion.¹⁹ A newer single-antibody test evaluating T-cell receptor beta constant chain 1 (TRBC1) expression detected clonality in all 56 T-LGLL patients tested, with 100 percent sensitivity and 85 percent specificity.²⁰ The imperfect specificity, though, reflects the earlier point about clonal T cells appearing in non-malignant settings. PCR-based clonality assays face the same limitation: they can detect a clone, but detecting a clone does not automatically equal cancer.⁶

Treatment Approaches

Many LGLL patients never need treatment. The decision to treat usually hinges on whether the patient has symptomatic cytopenias, recurrent infections from neutropenia, or transfusion-dependent anemia. When treatment is warranted, the first-line options are immunosuppressive drugs rather than traditional chemotherapy, reflecting the autoimmune flavor of the disease.²¹

Low-dose methotrexate is the most studied initial therapy for T-LGL leukemia. In a cohort of 36 patients, 86 percent responded to methotrexate alone or combined with prednisone, with a median time to response of about three months. However, the durability was moderate: the median response lasted 20 months, and responses were strongest in patients whose leukemic cells lacked STAT3 mutations.²² Cyclosporine is the main alternative first-line agent and works through a different immunosuppressive pathway. For patients who fail both, options thin out considerably, and there is active research into JAK-STAT pathway inhibitors as a more targeted approach.

The connection between STAT3 mutation status and treatment response is one of the more actionable findings in recent LGLL research. If your leukemic cells carry a STAT3 mutation, methotrexate alone may be less effective, and clinicians may lean toward cyclosporine or experimental agents earlier in the course. Mutation testing is increasingly becoming part of the initial workup.

Prognosis and What Affects It

For indolent T-LGL leukemia, the long-term outlook is generally favorable. Most patients live for many years, and the disease itself is rarely the direct cause of death. Infectious complications from neutropenia remain the primary risk. A study examining clinical outcomes found that overall survival was worse in male patients, those with elevated lactate dehydrogenase (a marker of cell turnover), and, somewhat counterintuitively, those without rheumatoid arthritis.²³ The RA finding likely reflects the fact that patients with RA are already under close medical surveillance and get diagnosed earlier, not that arthritis itself protects against the leukemia.

Aggressive NK-cell leukemia is a different story entirely. It progresses rapidly, responds poorly to treatment, and carries a grim prognosis. Fortunately, it is extremely rare. For the vast majority of people diagnosed with any form of LGLL, the disease is manageable with periodic monitoring and, when needed, immunosuppressive therapy.

LGLs After Organ Transplant and Bone Marrow Transplant

LGL expansions show up with surprising frequency in people who have received organ transplants or bone marrow transplants. In these settings, the immune system is simultaneously suppressed by medication and bombarded with foreign antigens from the graft. The result can be a clonal or oligoclonal LGL population that sometimes mimics LGLL on lab tests. Whether these post-transplant expansions represent true leukemia or an exaggerated immune response is often unclear, and many resolve or stabilize without specific treatment. Clinicians managing transplant recipients need to be aware of this overlap to avoid unnecessary alarm or, conversely, to catch the rare case that does progress.

The transplant context also highlights an underappreciated role of LGLs: graft-versus-leukemia effect. In bone marrow transplant recipients, donor-derived LGLs, particularly NK cells, can attack residual cancer cells in the host. This beneficial activity is one reason why NK-cell recovery after transplant is tracked closely. The same cells that can cause problems when they expand out of control are also among the immune system’s most potent weapons against cancer.